A Phase 4 interventional study of daunomycin/Idarubicin+ Silybinin and daunomycin/Idarubicin in Acute Myeloid Leukemia, Newly Diagnosed and Chemotherapy Effect, sponsored by Fujian Medical University Union Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-05-01.
Sponsored by Fujian Medical University Union Hospital · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 50 studies testing daunorubicin in Leukemia, Myeloid, Acute — 11 open to participants now, 16 under way, 4 of them phase 3. Daunorubicin · Leukemia, Myeloid, Acute.
Among the 50 studies testing daunorubicin in Leukemia, Myeloid, Acute, this one is the 25th largest by planned enrollment of the 48 interventional ones that give a count, is one of 2 that started in 2022, is the only one in phase 4, reaches primary completion later than 3 of the 15 other live ones, and was the 46th registered.
3,672 studies on the registry are indexed under Leukemia, Myeloid, Acute; 812 are open to participants now.
Browse Leukemia, Myeloid, Acute studies →11 of the 50 studies testing daunorubicin in Leukemia, Myeloid, Acute are open now, in 12 countries. Recruiting first, the newest first:
Sichuan Baili Pharmaceutical Co., Ltd. · Sites in China
Ages 18–75
Kura Oncology, Inc. · Sites in United States, Australia, Belgium and 14 more countries
Ages 18+
Richard Stone, MD · Sites in United States
Ages 18–75
National Cancer Institute (NCI) · Sites in United States, Canada, Puerto Rico
Ages 18–59
National Cancer Institute (NCI) · Sites in United States, Canada, Puerto Rico
Ages 18–59
By country, each count listing its studies:
Daunorubicin: first FDA approval 1979 (CERUBIDINE), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →
Of the 617 Leukemia, Myeloid, Acute studies recruiting now, 359 (58%) set no upper age limit and 219 (35%) stop at 75 or younger; 144 take children under 18; 29 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
50 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 16 · Phase 2 23 · Phase 3 14 · Phase 4 1
First in 1998; this study’s year is marked. 2 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 100 is above the median of 40 across 3,010 interventional studies indexed under Leukemia, Myeloid, Acute.
Median enrollment 111 across the 48 interventional studies. Of the 29 that completed or were terminated, 11 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 50 have an industry lead sponsor. The 10 most frequent:
Fujian Medical University Union Hospital is the lead sponsor of 109 studies on the registry; 79 are open to participants now.
Fujian Medical University Union Hospital has 4 studies filed under Leukemia, Myeloid, Acute — fewer than ten, so there is no comparison to draw.
4 of the studies testing daunorubicin in Leukemia, Myeloid, Acute that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07561892Fujian Medical University Union HospitalStudy of the Effectiveness and Safety of Daunorubicin /Idarubicin ± Silibinin in Treating Newly Diagnosed AML (Non-M3). | 2026-12-31 |
| NCT04801797Massachusetts General HospitalVenetoclax + Azacitidine vs. Induction Chemotherapy in AML | 2027-01-01 |
| NCT06313437Richard Stone, MDRevumenib in Combination With 7+3 + Midostaurin in AML | 2027-03-02 |
| NCT05554406National Cancer Institute (NCI)Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial) | 2027-03-31 |
Add all 4 to your calendar (.ics) → With an account.
Among the 50 studies testing daunorubicin in Leukemia, Myeloid, Acute, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Silibinin is the major active component of silymarin, a commonly used hepatoprotective agent. It stabilizes hepatocyte membranes, preserves cellular integrity, and accelerates DNA synthesis in liver cells. Clinically, it is widely used in the treatment of chronic persistent hepatitis, chronic active hepatitis, early-stage liver cirrhosis, and hepatotoxicity. Moreover, it has been reported to inhibit the growth and differentiation of various cancer cells, including hepatocellular carcinoma, prostate cancer, breast cancer, and cervical cancer.
Based on these preclinical findings, we aim to evaluate the efficacy and safety of combining silybinin with the standard first-line idarubicin/daunorubicin-based regimen in the treatment of newly diagnosed acute leukemia(non-M3)in a clinical setting.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The chmotherapy protocol includes daunomycin 60mg/m2/d or Idarubicin 10mg/m2/d for 3 days, at the same time, Silybin 200mg tid is administrated.
Drug: daunomycin/Idarubicin+ Silybinin
The chmotherapy protocol includes daunomycin 60mg/m2/d or Idarubicin 10mg/m2/d for 3 days
Drug: daunomycin/Idarubicin
Drug pages: DaunorubicinStudies of DaunorubicinDaunorubicin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · IdarubicinStudies of IdarubicinIdarubicin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · SilybinStudies of SilybinSilybin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
The chmotherapy protocol includes daunomycin 60mg/m2/d or Idarubicin 10mg/m2/d for 3 days, at the same time, Silybin 200mg tid is administrated.
Drug pages: DaunorubicinStudies of DaunorubicinDaunorubicin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · IdarubicinStudies of IdarubicinIdarubicin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
The chmotherapy protocol includes daunomycin 60mg/m2/d or Idarubicin 10mg/m2/d for 3 days
overall remission rate (ORR)
subjects achieving complete remission (CR) or partial remission (PR) at the end of cycle 1and cycle 2(each cycle is 1 month)
Time frame: At the end of Cycle 1 and Cycle 12 (each cycle is 1 month)
overall survival (OS)
subjects survival after treatment are finished
Time frame: 1-year
Time to Response(TTR)
The time from initiation of the study treatment to the first documentation of CR or PR.
Time frame: 1-2months(1-2 courses)
Duratin of Response(DOR)
The time from first documentation of CR to the first documented disease progression or death, whichever occurs first
Time frame: 1-year
Progression-Free Survival(PFS)
The time interval from the start of the study treatment to the first documentation of disease progression or death from any cause,whichever occurs first
Time frame: 1-year
Plan to share: No
No publications or documents are linked to this record.
Started Apr 2022 (actual). Primary completion is estimated for Dec 2026, 56 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Daunorubicin · Idarubicin · Silybin
Fujian Medical University Union Hospital →